Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?
暂无分享,去创建一个
G Duker | L. Carlsson | G. Amos | G. Duker | L Carlsson | L Drews | G J Amos | B Andersson | G Wadstedt | B. Andersson | L. Drews | G. Wadstedt | Birgit Andersson | Gunilla Wadstedt
[1] E. Carmeliet. Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. , 1992, The Journal of pharmacology and experimental therapeutics.
[2] G. Gintant,et al. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. , 1991, Circulation research.
[3] N. Yoshida,et al. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. , 1993, Arzneimittel-Forschung.
[4] D. Wyse,et al. Melperone: Electrophysiologic and Antiarrhythmic Activity in Humans , 1990, Journal of cardiovascular pharmacology.
[5] D. Roden. Current status of class III antiarrhythmic drug therapy. , 1993, The American journal of cardiology.
[6] G. M. Briggs,et al. 4,5-Dihydro-3-(methanesulfonamidophenyl)-1-phenyl-1H-2,4-benzodiazepines: a novel class III antiarrhythmic agents. , 1995, Journal of medicinal chemistry.
[7] M Gwilt,et al. Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines. , 1990, Journal of medicinal chemistry.
[8] L. Carlsson,et al. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. , 1993, Cardiovascular research.
[9] B. Yeğen,et al. The hypotensive effect of cisapride in rat. , 1994, General pharmacology.
[10] G Duker,et al. Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031. , 1993, Cardiovascular research.
[11] I. Dubrow,et al. Cisapride-induced long QT interval: what is the role of ranitidine? , 1997, The Journal of pediatrics.
[12] J. Schuurkes,et al. Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. , 1985, The Journal of pharmacology and experimental therapeutics.
[13] D. Wysowski,et al. Cisapride and fatal arrhythmia. , 1996, The New England journal of medicine.
[14] M E Sullivan,et al. An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. , 1992, Progress in medicinal chemistry.
[15] W. A. Murray,et al. Long QT syndrome during high-dose cisapride. , 1995, Archives of internal medicine.
[16] Thomas M. Argentieri,et al. Potassium channel blockers as antiarrhythmic drugs , 1994 .
[17] T. Karasawa,et al. Comparison of gastrokinetic effects of AS-4370, cisapride and BRL24924 , 1990 .
[18] B. Dumotier,et al. Cisapride‐induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres , 1996, British journal of pharmacology.
[19] L. Wiseman,et al. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. , 1994, Drugs.
[20] L. Carlsson,et al. QTU‐Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the Rabbit: Etiology and Interventions , 1990, Journal of cardiovascular pharmacology.
[21] J E Axenborg,et al. A PC-based on-line system for physiological in vivo and in vitro experiments. , 1993, Computer methods and programs in biomedicine.
[22] R. Lazzara,et al. Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart. , 1996, Journal of cardiovascular pharmacology.
[23] J. K. Gibson,et al. Comparative Assessment of Ibutilide, D‐Sotalol, Clofilium, E‐4031, and UK‐68, 798 in a Rabbit Model of Proarrhythmia , 1993, Journal of cardiovascular pharmacology.
[24] S. Wolfe,et al. Cisapride and torsades de pointes , 1995, The Lancet.
[25] H. Tan,et al. Electrophysiologic Mechanisms of the Long QT Interval Syndromes and Torsade de Pointes , 1995, Annals of Internal Medicine.
[26] E. Aliot,et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.
[27] R. McCallum. Cisapride: a new class of prokinetic agent. The ACG Committee on FDA-related matters. American College of Gastroenterology. , 1991, The American journal of gastroenterology.
[28] J. Schuurkes,et al. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. , 1995, Pharmacological reviews.